// App-Quantinova.ai

4548 : Association of C-reactive protein (CRP) with efficacy of avelumab + axitinib (A + Ax) in advanced renal cell carcinoma (aRCC): Long-term follow-up results from JAVELIN Renal 101.

Researchers

Presenter

  • Yoshihiko Tomita

Principal Investigators

  • James Larkin

  • Balaji Venugopal

  • John B. A. G. Haanen

  • Hiro-Omi Kanayama

  • Masatoshi Eto

  • Marc-Oliver Grimm

  • Yosuke Fujii

  • Yoshiko Umeyama

  • Mariangela Mariani

  • Alessandra Di Pietro

  • Toni K. Choueiri

Medical Centers

  • Nigata University Graduate School of Medical and Dental Sciences, Japan

  • The Royal Marsden Hospital NHS Foundation Trust, London & Surrey, United Kingdom

  • University of Glasgow, Glasgow, United Kingdom

  • Netherlands Cancer Institute (NKI), Amsterdam, Netherlands

  • Department of Urology, Graduate School, The University of Tokushima, Tokushima, Japan

  • Department of Surgery and Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan

  • Department of Urology, Universitaetsklinikum Jena, Jena, Germany

  • Pfizer R&D Japan

  • Tokyo, Japan

  • Pfizer Inc, Milan, Italy

  • Dana-Farber Cancer Institute, Lank Center for Genitourinary Oncology, Boston, MA

Locations

  • Japan

  • United Kingdom

  • Netherlands

  • Germany

  • Italy

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Nephrology

  • Oncology (ONC)

Disease

  • Metastatic Renal Cell Cancer

Biomarkers

  • C reactive protein

Drug/Treatment

  • Inlyta

  • Avelumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • NCT02684006

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved